- Home
- CLLS vs DMAC Comparison
CLLS vs DMAC Comparison
Compare CLLS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- DMAC
- Stock Information
- Founded
- CLLS 1999
- DMAC 2000
- Country
- CLLS France
- DMAC United States
- Employees
- CLLS N/A
- DMAC N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- DMAC Health Care
- Exchange
- CLLS Nasdaq
- DMAC Nasdaq
- Market Cap
- CLLS 299.0M
- DMAC 310.1M
- IPO Year
- CLLS 2007
- DMAC N/A
- Fundamental
- Price
- CLLS $3.15
- DMAC $7.13
- Analyst Decision
- CLLS Buy
- DMAC Strong Buy
- Analyst Count
- CLLS 1
- DMAC 3
- Target Price
- CLLS $4.00
- DMAC $12.33
- AVG Volume (30 Days)
- CLLS 76.4K
- DMAC 443.2K
- Earning Date
- CLLS 11-03-2025
- DMAC 11-12-2025
- Dividend Yield
- CLLS N/A
- DMAC N/A
- EPS Growth
- CLLS N/A
- DMAC N/A
- EPS
- CLLS N/A
- DMAC N/A
- Revenue
- CLLS $63,438,000.00
- DMAC N/A
- Revenue This Year
- CLLS N/A
- DMAC N/A
- Revenue Next Year
- CLLS $66.76
- DMAC N/A
- P/E Ratio
- CLLS N/A
- DMAC N/A
- Revenue Growth
- CLLS 223.09
- DMAC N/A
- 52 Week Low
- CLLS $1.10
- DMAC $3.19
- 52 Week High
- CLLS $3.35
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- CLLS 54.47
- DMAC 56.39
- Support Level
- CLLS N/A
- DMAC $6.83
- Resistance Level
- CLLS $3.35
- DMAC $7.46
- Average True Range (ATR)
- CLLS 0.15
- DMAC 0.38
- MACD
- CLLS -0.09
- DMAC -0.33
- Stochastic Oscillator
- CLLS 94.03
- DMAC 95.66
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.